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On 30 January, Bill Gates, Margaret Chan, the Director-
General of the World Health Organization, CEOs of
major pharmaceutical companies, senior government
officials from donor and endemic countries gathered in
London together with NGOs and academic institutions,
at a meeting entitled “Uniting to Combat NTDs: End-
ing the Neglect and Reaching the 2020 Goals” http://
www.unitingtocombatntds.org to announce a massive
expansion of the support to control and potentially
eliminate or eradicate a group of seventeen Neglected
Tropical Diseases. The meeting was convened by the
Bill and Melinda Gates Foundation. Since 2004 there
has been a gradual but increasing recognition of the
importance of neglected tropical diseases (NTDs) as an
impediment to development. If the Millennium Devel-
opment Goals (MDGs), which relate to health, are to be
achieved then controlling only HIV, tuberculosis and
malaria will not alone address the needs of the poorest.
It is essential the so called “other diseases” of the MDGs
are given a high priority on the global Health agenda.
The London meeting is the culmination of the efforts by
many interested partners from diverse constituencies.
These groups working together, since the publication in
2010 of the first WHO Report” Working to overcome
neglected Tropical Diseases” have recognised the impor-
tance of NTDs as impediments to development. It is
also important to note that these conditions touch the
“bottom billion” but can be addressed either with avail-
able tools or through targeted research to develop new
products and tools within an acceptable time frame to
address well defined needs. Endemic countries, interna-
tional agencies, bilateral and philanthropic donors, aca-
demia and non- governmental organisations as well as
existing global partnership organisations are coming
together- all committed to achieving unprecedented
cooperation to solve a major health problem. The
London meeting was a landmark in public health coop-
eration setting the agenda for the next decade. The
commitments made will bring hope providing the final
nail in the coffin of diseases which have plagued human-
ity for millennia. All parties present endorsed the “Lon-
don” Declaration inspired by WHO’s Road Map on
NTDs published on the 26th January. The road map sets
targets for the period 2012-2020. WHO believes that
despite the complexity of the NTDs, the targets are
achievable. The Declaration commits partners to sustain
and expand resources to achieve ambitious but well-
defined and obtainable eradication, elimination or con-
trol targets. Partners will advance research and develop-
ment, enhance collaboration on NTDs at national and
international levels, work more effectively together,
enable adequate funding for endemic countries to
implement programmes, provide the technical support
for evaluation and monitoring and provide regular
updates towards the 2020 goals. The diseases embraced
by this global movement do not have any formally
structured single partnership but all constituencies share
a strong commitment to support WHO’s strategies,
goals and targets.
These diseases have not suddenly emerged; they have
been the subject of studies since the earliest days of the
discipline of Tropical Medicine where the father of that
discipline, Sir Patrick Manson, first discovered that
insects were capable of transmitting infective agents
when he discovered the mosquito transmission of filarial
infections in China in 1879. During the last 8 years the
messages articulated by advocates of NTD eradication,
elimination and control have gradually been recognised
by global health leaders and policy makers as amongst
the best investments that a health dollar can buy. The
term Neglected Diseases emerged in the 1980’s when
the late Dr Ken Warren as Head of the Rockefeller
health department introduced the term Great Neglected
Diseases. The term fell into abeyance until it was
adopted at the Berlin meetings of 2003 and 2004 orga-
nised by WHO and Deutsche Gesellschaft fur
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Technissche (now Internationale) Zusammenarbeit
(GTZ). WHO then created a specific Department of
Control of Neglected Tropical Diseases and started to
develop policies recognising the need for integration of
approaches and the increasing volume and diversity of
drug donations, culminating in the huge increase in the
donations. The transition from neglect to a high level of
priority can be attributed to a concerted effort on the
part of partners who have embraced the message of
need, burden of disease, availability of effective donated
and safe drugs and the proven successes. Following the
meeting in London substantial progress to address the
needs for NTD eradication, elimination and control
have been met. However, partnership, innovation, and
additional resources will still be needed. This is a great
leap forward while still keeping the space for more to
join a transformative movement by “working together in
an innovative, flexible and cost effective way” as articu-
lated by the Margaret Chan, the Director General of
WHO. New commitments announced in London of par-
ticular importance are the expanded donations of prazi-
quantel for schistosomiasis, the most important tropical
disease in Africa after malaria, and ambisome for visc-
eral leishmaniasis. In the broader context that twelve of
the worlds biggest pharmaceutical companies have col-
lectively committed to extend their donations through
2020 to help meet the WHO control and elimination
goals is remarkable. Earlier in January the UK Depart-
ment for International Development announced a five-
fold increase in resources for NTDs. The resources for
Guinea Worm Eradication have been fully provided for
by a consortium of donors-the UK Department for
International Development, the Bill and Melinda Gates
Foundation, the President of the United Arab Emirates
and the Children’s Investment Fund Foundation. In
addition the World Bank will offer NTD endemic coun-
tries new resources to build community health systems
as well as work to expand the Onchocerciasis Trust
Fund to other NTDs.
Two years ago I wrote a Comment for the Lancet
introducing a Series on NTDs entitled “Neglected Tro-
pical Diseases-beyond the tipping point?” Now I believe
it would be safe to remove that question mark. The
London meeting with its remarkable commitments from
all partners and the accompanying Declaration is a Glo-
bal Health turning point. A decade ago few programmes
had adequate resources for implementation and were
acting in isolation. There was limited cross- talk
between the disease specific communities or recognition
of the synergistic impacts of drugs, the tools for evalua-
tion were less refined, research was poorly funded and
less focussed, there was limited NGDO involvement and
coordination and less endemic country commitment-
there has been a “sea change”. NGDOs have also been
“visionary"; those which a traditionally focussed on
blindness have recognised that the systems in place for
implementation of ivermectin for onchocerciasis control
can also address other disabilities.
A global consensus that actually addresses the low
hanging fruit of NTD control, elimination and eradica-
tion with the largest donations ever made by a group of
all the major pharmaceutical donors is a vital contribu-
tion to health and development. This is real and trans-
parent progress made over a decade when the existing
programmes were truly neglected and struggling for
recognition on the Global Health agenda. The change of
paradigm to the concept of an “NTD” brand based on
integrated control or elimination was a crucial decision.
This was communicated through strong and visionary
leadership in the World Health Organization (WHO)
who established an NTD Department. This was a critical
bedrock for consistent policy and leadership as new
policies and norms were articulated- a pre-requisite to
advocate for the necessary donations. It is important to
recall as we move towards a new era of elimination of
at least some NTDs that the principles and rationale for
pro-poor and non-discriminatory interventions also
relate to equity, human rights, access to essential medi-
cines, strengthening of health systems and enhanced
capacity development.
Over recent years there has been massive up-scaling of
country commitment, proven successes of implementa-
tion strategies, increased drug donations and hugely
increased bilateral and philanthropic support. The Lon-
don Declaration provides the platform for the next 8
years- a statement with which no one can argue. How-
ever, whatever the perceived success of reaching the
level of recognition that the NTD brand has now
achieved we must look forward. As a committed com-
munity we have now acquired new resources and brand
identity. This brings responsibility and obligations.
A primary responsibility is to our donors, the tax-
payers of the developed world struggling with economic
uncertainty. It is remarkable that there has been such a
generous responses from the UK and US governments
in the current environment. It is essential that we pro-
vide value for money; the taxpayer identifies with HIV/
AIDS, malaria and TB but certainly less with the NTDs.
Our argument for taking that responsibility is that we
provide more health to more people for less money. As
a community it behoves us to remember that the value
of the donated products from the pharmaceutical part-
ners is between US$2-3 BILLION annually. Another
responsibility is to ensure that these donations are used
efficiently and effectively and this links to the final
responsibility- of ensuring the drugs reach the commu-
nities who are the ultimate beneficiaries; NTD pro-
grammes based on preventive chemotherapy have an
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enviable therapeutic coverage record but we know we
have to go further and faster by expanding geographic
coverage.
These responsibilities should be driving our thinking.
What should we have now on the agenda as we look
towards the 2020 horizon? Clearly we need to maintain
our advocacy and build on successes. We need to do
several things to maintain the momentum and fulfil our
responsibilities.
First, we must manage these huge drug donations in
the most effective way. These precious, high quality
commodities for the most neglected populations are the
key to our progress and success and are a major reason
for the position we now find ourselves in. Poor people,
as Roy Vagelos knew when he announced the donation
of ivermectin in 1987, cannot afford even the cheapest
of drugs; the only way to satisfy demand was to donate
them. That decision still deserves recognition as it was
the starting point for the current movement. In the
coming years WHO has a key role to play maintaining
its core leadership function of developing policy and
responding to and representing member states and
ensuring the drug donations are effectively managed.
This is critical.
Secondly, we must, if we are to succeed, find a new
way of working together to reflect the new reality of
financial resources; this will require flexibility, open and
transparent communication and above all the need to
subjugate our institutional and organisational sensitiv-
ities to achieve the greater good. New models and think-
ing will be required. This will be one of the guiding
principles of the newly established UK Coalition against
NTDs which brings together UK strengths from the dif-
ferent interested sectors http://www.ntd-coalition.org.
Academia, NGDOs, the education sector and the differ-
ent disease specific communities will facilitate cross talk
and maximise the leverage we can obtain through their
networks. The Coalition pledges to promote the London
Declaration by words and actions and work with all
partners, particularly the endemic countries, the phar-
maceutical sector and WHO. We believe that the power
of the UK Coalition lies in its historic institutional
research commitment dating to the early part of the last
century together with the NGDO implementation
record in partner countries and its traditional associa-
tion with WHO. In short the impact of the whole will
be greater than the constituent parts.
Thirdly, a further need we must address is the deficit
in human capacity. This is not just programme manage-
ment capacity but the NTD research capacity in Africa.
The European Union Foundation Initiative for NTDs
(EFINTD) meeting in Maputo brings together the
resources of five Foundations- Cariplo, Gulbenkian,
Merieux, Nuffield and Volkswagen, in a unique
partnership to provide resources over the longer term
for African Fellowships. The current Fellows appointed
three years ago have met regularly; they have established
there own networks of collaboration, grown in confi-
dence and achieved scientific independence. The
Maputo will meeting bring together existing post-doc-
toral Fellows and will select another group, through a
competitive process. Some 20 Fellows are already in
place mentored by European institutional partners. This
initiative fills a gap and has demonstrated there exists
an untapped yet enthusiastic pool of human resources
who, given a small amount of support, will be the next
generation of scientists to take forward both the basic
and operational research agendas for NTDs and articu-
late future policy.
Fourthly, the NTD community cannot stand still. We
have disease specific targets and the constituencies who
are fully aware of the research needs; those communities
are profoundly grateful for the support from the Bill and
Melinda Gates Foundation as well as other Foundations
and funding agencies which support basic and applied
research. The needs are well recognised. Complacency
about the efficacy of existing products is not appropriate
as there is rarely a perfect tool. Given the long time-
lines of getting new products into practice we have the
obligation to move quickly with the products we have
and to be aware of the potential risks and pitfalls. These
can be tackled, as has been often demonstrated. How-
ever, there are other areas of neglect that we need to
address. We have forgotten the neglected zoonotic dis-
eases which interface with the many millions of those
dependent on livestock as their sole asset and whose
livestock, as well as themselves, succumb to zoonotic
infections which are often undiagnosed and unreported.
There is also the added dimension of co-morbidity of
NTDs. In particular that of the burden of mental illness
imposed on the sufferers themselves and their carers.
The numbers and consequent burden of depression
engendered by the stigma, social exclusion and eco-
nomic impact has not been considered or addressed. A
further dimension is the need for health systems
research a difficult subject to address and often setting
specific and hence difficult for results to be generalisa-
ble. These are just some ideas for consideration as we
move forward towards 2020.
In conclusion I must focus on the most important
issue - that of equity so elegantly expressed in the quote
on the front cover of the Lancet two years ago following
Bernhard Liese’s work “Only 0.6% of overseas develop-
ment assistance for health is allocated to neglected
tropical diseases, despite such diseases affecting at
least 1 billion people”. This figure is and remains
unacceptable when, for such trivial sums, we can make
a massive impact. The recent commitments may indeed
Molyneux Parasites & Vectors 2012, 5:23
http://www.parasitesandvectors.com/content/5/1/23
Page 3 of 4
go some way to changing the 0.6% figure. However, in
terms of the donated drugs which have been such an
important a base for the NTD momentum I come back
to the view that if we, as an international community of
partners, cannot deliver high quality, donated drugs
which have proven multiple impacts then we cannot
expect more complex problems of international health
to be solved. The NTD community has the opportunity
over the next few years to make the massive progress
towards eliminating permanently diseases which for far
too long have been more than neglected, they have been
ignored.
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